Physician profile
Mark Stephens
NPI 1093370603
$2,812.39
in general payments reported to CMS, 2019-2025
10 companies · $994 in 2025
The $994 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $173 · 2023: $1,208 · 2024: $289 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647 · Travel and Lodging: $829 · Education: $15.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.63 |
| Travel and Lodging | $828.65 |
| Education | $15.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Icotec Medical INC. | $1,100.13 | 2023 | Icotec Blackarmor Spine System |
| Integra Lifesciences Corporation | $410.08 | 2022-2025 | Codman Hakim, Cusa Clarity, Codman Certas |
| Cerapedics INC. | $342.47 | 2024-2025 | I-Factor Peptide Enhanced Bone Graft |
| Stryker Corporation | $225.91 | 2022-2025 | Surpass Evolve |
| Kuros Biosciences USA, INC | $174.40 | 2025 | Magnetos |
| Penumbra, INC. | $148.00 | 2021 | |
| Depuy Synthes Sales INC. | $148.00 | 2025 | Synthecel |
| Boston Scientific Corporation | $121.04 | 2024 | General - Dbs |
| Irras USA, INC. | $107.99 | 2023 | |
| Zimmer Biomet Holdings, INC. | $34.37 | 2025 | Gel-One Cross-Linked Hyaluronate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.